Company news
Rallybio Corporation news in 2025
Rallybio Corporation's news releases, calls and decks from 2025, newest first.
Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates
November 6, 2025
Rallybio Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic, Pharmacodynamic Study
September 26, 2025
Rallybio Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study
September 25, 2025
Rallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 Program
September 3, 2025
Rallybio Reports Second Quarter 2025 Financial Results and Provides Business Updates
August 7, 2025
Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals
July 8, 2025
ImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of Directors
July 7, 2025
Affibody’s licensee Rallybio Announces Initiation of Dosing with RLYB116 in Phase 1 Confirmatory PK/PD Study
June 13, 2025
Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study
June 12, 2025
Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates
May 8, 2025
Rallybio to Present at the 2025 Citizens JMP Life Sciences Conference
April 29, 2025
Rallybio to Discontinue Development of RLYB212 for Prevention of FNAIT
April 8, 2025
Rallybio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
March 13, 2025
Rallybio to Present at the TD Cowen 45th Annual Health Care Conference
February 25, 2025
Rallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial
February 10, 2025
Rallybio Highlights 2024 Accomplishments and Anticipated Milestones for 2025
January 9, 2025